<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141109">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01739283</url>
  </required_header>
  <id_info>
    <org_study_id>H-2-2009-078 33269</org_study_id>
    <nct_id>NCT01739283</nct_id>
  </id_info>
  <brief_title>GIP and GLP-1 in Type 1 Diabetes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mikkel Christensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <authority>Denmark: Danish Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of Glucose-dependent Insulinotropic Polypeptide (GIP) effects at hyper and
      hypoglycemia in type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>plasma glucagon area under curve values</measure>
    <time_frame>approx. 15 minutes intervals, time 0 to 120 min</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma gut hormones and nutrients (absolute, incremental and area under curve values)</measure>
    <time_frame>approx. 15 minutes intervals, time 0 to 120 min</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Glucose and glycerol tracer kinetics</measure>
    <time_frame>approx. 15 minutes intervals, time 0 to 120 min</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>glucose (g/kg body weight) needed to be infuse to keep clamp</measure>
    <time_frame>approx. 15 minutes intervals, time 0 to 120 min</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>hyperglycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperglycemic clamping</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypoglycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypoglycemic clamping</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GIP</intervention_name>
    <arm_group_label>hyperglycemia</arm_group_label>
    <arm_group_label>hypoglycemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <arm_group_label>hypoglycemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>hyperglycemia</arm_group_label>
    <arm_group_label>hypoglycemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Diagnosed with type 1 diabetes (WHO criteria)

        Exclusion Criteria:

          -  HbA1c &gt; 9 %

          -  Liver disease (ALAT/ASAT &gt; 2 x upper normal limit)

          -  Diabetic nephropathy (s-creatinine &gt; 130 µM or albuminuria)

          -  Proliferative diabetic retinopathy (anamnestic)

          -  Severe arteriosclerosis or heart failure (NYHA group III or IV)

          -  Anemia

          -  treatment with medication not applicable to pause for 12 hours

          -  C-peptide increase after 50 g iv arginine
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikkel Christensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital Gentofte</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikkel Christensen, Christensen</last_name>
    <phone>+45 39773320</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikkel Christensen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 31, 2013</lastchanged_date>
  <firstreceived_date>November 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Mikkel Christensen</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
